Merck KGaA Acquires AmpTec to Strengthen its mRNA Capabilities for Vaccines- Treatments and Diagnostics
Shots:
- The acquisition will integrate AmpTec’s PCR-based mRNA technology with Merck’s expertise in lipids manufacturing- providing combine offering across mRNA value chain
- The deal will expand Merck’s capabilities to develop & manufacture mRNA for use in vaccines- treatments- and diagnostics applicable in COVID-19 and many other diseases. Additionally- AmpTech’s diagnostic business focusing on customized long RNAs and DNAs for IVDs- complements existing Merck’s portfolio
- The addition of AmpTech’s PCR-based technology to Merck allow the companies to offer innovative technologies- products- and services- advancing life-enhancing therapies
Ref: Merck KGaA | Image: Merck KGaA
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com